Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT02413736 : Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-100Age 18-100

Sarcoma<br/>CancersCancer LocationSarcoma

Systemic therapy | SarcomaGastrointestinal stromal tumour (GIST)

Trial Overview Read MoreRead more

This phase III study is evaluating whether receiving targeted therapy (imatinib) for three or five years is more effective in people with gastrointestinal stromal tumours following surgery.

This trial is treating patients with gastrointestinal stromal tumours.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

Commercial Sponsor

Heikki Joensuu


This study is recruiting people who have verified gastrointestinal stromal tumour (GIST) with a high risk of recurrence, despite removal of all macroscopic GIST tissue during surgery and having received 3 years of adjuvant imatinib. Study participants will be randomly allocated to either Arm A or Arm B. In Arm A (Experimental), participants will continue receiving imatinib (400mg/day for 24 months). In Arm B, participants will stop receiving imatinib. All participants will be followed up using blood tests and scans of the abdomen.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Ms Eleanor Edwards
03 9076 2297

PCCTU (Parkville Cancer Clinical Trials Unit) *
Enquiries Line Coordinator
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.